Colistin Dosing
For adults with normal renal function, administer a loading dose of 9 million units (MU) of colistimethate sodium (CMS) followed by a maintenance dose of 4.5 MU twice daily, with dose adjustments based on creatinine clearance for renal impairment. 1
Standard Dosing for Normal Renal Function
The most recent international guidelines from 2022 provide clear dosing recommendations based on pharmacodynamic studies in critically ill patients 1:
- Loading dose: 9 MU CMS (equivalent to 5 mg/kg colistin base activity)
- Maintenance dose: 4.5 MU CMS every 12 hours
This can also be expressed using the formula: 2.5 mg × (1.5 × CrCl + 30) IV every 12 hours for the maintenance dose 2
The loading dose is critical because CMS converts slowly to active colistin, and without it, therapeutic concentrations are delayed by 24-48 hours 3, 4.
Dose Adjustment for Renal Impairment
Creatinine clearance is the primary determinant of colistin dosing 1, 5. The FDA-approved dosing schedule provides specific adjustments 6:
Renal Function Categories:
- CrCl ≥80 mL/min: 2.5-5 mg/kg/day divided into 2-4 doses
- CrCl 50-79 mL/min (Mild): 2.5-3.8 mg/kg divided into 2 doses per day
- CrCl 30-49 mL/min (Moderate): 2.5 mg/kg once daily or divided into 2 doses
- CrCl 10-29 mL/min (Severe): 1.5 mg/kg every 36 hours
Maximum daily dose should not exceed 5 mg/kg/day with normal renal function 6.
Critical Dosing Considerations
Important Caveats:
Serum creatinine may underestimate renal function - Consider using cystatin C or 24-hour urine clearance for more accurate assessment, particularly in critically ill patients 7. Relying solely on serum creatinine can lead to overdosing and neurotoxicity.
Patients with CrCl ≥80 mL/min are at risk of underdosing - Even maximum recommended doses may fail to achieve therapeutic targets in 60% of patients with preserved renal function 8, 9. Consider combination therapy in these cases.
Obese patients: Base dosing on ideal body weight, not actual body weight 6.
Renal replacement therapy: Patients on hemodialysis or continuous renal replacement therapy require supplemental dosing due to significant extracorporeal clearance (up to 67% of total drug clearance) 5. The loading dose remains 9 MU, with maintenance adjusted based on RRT modality.
Monitoring Requirements
Renal function must be monitored closely during therapy 1:
- Check creatinine clearance at baseline and every 2-3 days during treatment
- Acute kidney injury occurs in 3-15% of patients 10, 11
- Risk is highest in elderly patients and those with pre-existing chronic kidney disease 1, 11
- Avoid concomitant nephrotoxic agents when possible 6
Neurotoxicity Warning
Dose-dependent neurological effects can occur 6, 7:
- Circumoral paresthesia, extremity tingling, vertigo, dizziness, slurred speech
- Warn patients not to drive or operate machinery
- Symptoms typically resolve with dose reduction
- Severe cases may present as acute confusional state with hallucinations, particularly with drug accumulation in renal impairment 7
Pharmacodynamic Target
The goal is to achieve an average steady-state plasma concentration (Css,avg) of ≥2 mg/L for clinical efficacy while staying <4 mg/L to minimize nephrotoxicity 8, 9. However, standard dosing regimens often fail to achieve these targets, particularly when the organism's MIC is ≥1 mg/L 10.
When Standard Dosing May Be Inadequate
Consider combination therapy rather than dose escalation when 1:
- MIC ≥1 mg/L
- CrCl ≥80 mL/min (augmented renal clearance)
- Monotherapy fails to achieve clinical response
The evidence for combination therapy is controversial, but it may be necessary when adequate drug exposure cannot be safely achieved with monotherapy 1.
Administration Routes
Intravenous administration 6:
- Direct intermittent: Inject half the daily dose over 3-5 minutes every 12 hours
- Continuous infusion: Inject half the daily dose over 3-5 minutes, then infuse the remaining half over 22-23 hours
Intramuscular administration: Deep IM injection into large muscle mass; use within 7 days if stored at 2-8°C 6
Conversion Note
1 million IU colistin ≈ 30 mg colistin base activity (CBA) ≈ 80 mg colistimethate sodium 2. Always verify which formulation and unit of measurement is being used to avoid dosing errors.